Phase 2 N=83 Eribulin in HER2 Negative Metastatic BrCa
Breast Cancer
Primary: Overall Response Rate (ORR) — 35.6; 13.2 percentage of participants — p=0.42
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=35 PET/CT Imaging Companion Study To ACTG A5314
HIV · Inflammation · Atherosclerosis
Primary: Change in Arterial FDG Uptake (From Baseline) in the Most Diseased Segment — -0.126; 0.026 TBR
Phase 2 N=171 BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A) — 1.7; 75.9; 74.5 percentage of…
Phase 2 N=35 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma Relapsed · Diffuse Large B Cell Lymphoma Refractory
Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants
N/A N=209 Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery
Conditions Requiring Colorectal Surgery
Primary: Mean Pain Score — 3.0; 2.4 score on a scale — p=0.007
N/A N=38 interACTION: A Portable Joint Function Monitoring and Training System for Remote Rehabilitation Following TKA
Total Knee Arthroplasty
Primary: Value Was Evaluated as the Ratio of Change in the Activities of Daily Living Scale Score to the Costs of Rehabilitation. — 0.013; 0.018 ratio
N/A N=63 SpO2 System Accuracy Testing With Different Sensors
Pulse Oximetry
Primary: Accuracy Root Mean Square (ARMS) — 1.488; 1.465; 1.651; 1.352 Accuracy Root Mean Square
Phase 2 N=156 Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Extensive Stage Small Cell Lung Carcinoma · Large Cell Lung Carcinoma · Neuroendocrine Carcinoma
Primary: Recommended Phase II Dose (Phase I) — 100 mg
Phase 2 N=24 Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
Recurrent Mycosis Fungoides and Sezary Syndrome · Refractory Mycosis Fungoides and Sezary Syndrome · Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7
Primary: Objective Response Rate (ORR), Defined as a Confirmed Partial Response (PR) or Complete Response (CR) Using Global Assessment Standard Response Criteria for Mycosis…
Phase 3 N=493 Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder
Bipolar Disorder · Depression
Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) — -12.4; -14.8; -14.1 score on a scale — p=0.0417
Phase 3 N=744 A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
Acne Vulgaris
Primary: Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 — -17.0; -15.4 Lesions — p=0.2301
Phase 4 N=248 A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise
Bronchospasm · Activity/Exercise Induced Bronchospasm
Primary: Maximal Percent Change in Forced Expiratory Volume in 1 Second (FEV1) Following Exercise Challenge at Week 4 — -9.5; -12.7 Percent change — p=0.021
Phase 3 N=748 A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
Acne Vulgaris
Primary: Long-Term Safety Assessed Through Adverse Events and Local Skin Reactions — 197; 124; 18; 402 Participants
N/A N=174 Comparison of Oxygenation and Ventilation With a Novel Nasal Mask Versus Standard of Care During Colonoscopy
Colonoscopy · Oxygenation · Ventilation
Primary: Time to First Intervention — 10; 19 minutes
Phase 2 N=13 Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease
Sickle Cell Disease · Sickle Cell Nephropathy
Primary: Change From Baseline to Week 6 in Endothelial Function — 1.44; 0.69 % diameter change — p=0.51